Clinical Trials in the USA / NCT06832410
Recruiting
Phase 3
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
NCT06832410 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Type 1 DiabetesKidney Transplant
Investigational drug(s) / intervention(s)
Biological/Vaccine: Infused into the hepatic portal vein.
Study summary
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Eligibility
Key Inclusion Criteria:
* Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence
* Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks
* Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study
Key Exclusion Criteria:
* Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks
* Participants had \>1 kidney transplant procedure
Other protocol defined Inclusion/Exclusion criteria may apply.
Primary outcome measure(s)
- Proportion of Participants who are Insulin Independent — At 1 year After VX-880 infusion
Trial sites (7)
| Facility | City | Region | Status |
|---|---|---|---|
| Perelman Center for Advanced Medicine - Endocrinology | Philadelphia | Pennsylvania | Recruiting |
| Montefiore Clinical and Translational Research Center - Endocrinology | Pittsburgh | Pennsylvania | Recruiting |
| UW University Hospital - Endocrinology | Madison | Wisconsin | Recruiting |
| Toronto General Hospital - Endocrinology | Toronto | Canada | Recruiting |
| Vancouver General Hospital - Gordon and Leslie Diamond Health Care Centre | Vancouver | Canada | Recruiting |
| King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology | Riyadh | Saudi Arabia | Recruiting |
| King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology | Riyadh | Saudi Arabia | Recruiting |
More Vertex Pharmaceuticals Incorporated trials in the USA
A Long-term Follow-up Study in Participants Who Received CTX001
Enrolling by invitation
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
Recruiting
Other trials for the same condition
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
Active, not recruiting
The iLet Experience Study
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06832410 on ClinicalTrials.gov ↗ ← All trials in the USA